PT-141 (Bremelanotide)
- Ships from Canada in 24hrs
- Free Express Post over $200
- Third-party lab verified
- Secure NxtPay checkout
Key Health Benefits:
-
Enhances libido in men and women.
-
Supports Treatment of Sexual Dysfunction
-
Non-vascular Mechanism
-
Improves Mood and Well-being
Need supplies?
Get all the reconstitution & injection supplies.
Bacteriostatic Water$12.50
Injection Syringes$16.50
Alcohol Pads$8.90
About PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is a synthetic peptide to treat sexual dysfunction, particularly low libido in both men and women. Unlike other treatments that work by targeting the vascular system (such as Viagra), PT-141 operates through the central nervous system. It activates melanocortin receptors in the brain, which are directly involved in stimulating sexual arousal, making it suitable for those who may not respond to or are unable to use traditional ED medications. Initially derived from Melanotan II—a peptide known for its tanning effects—PT-141 was discovered to have significant potential in enhancing sexual desire, leading to its targeted use for libido enhancement.
Peer-reviewed studies on PT-141
- (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences.Read source ↗
- (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research.Read source ↗
- (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research.Read source ↗
- (2006). An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist. The Journal of Sexual Medicine.Read source ↗
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology.PMID 31599840Read source ↗
Reviews
Loading reviews…
Related Products
3 cited studiesAll PeptidesRetatrutide
$90.00& upConcentration
9 cited studiesAll PeptidesBPC-157
$30.00& upConcentration
6 cited studiesAll PeptidesGHK-CU
$65.00& upConcentration
4 cited studiesAll PeptidesTesamorelin
$70.00& upConcentration
Peptides are research compounds and are not approved for human use unless prescribed by a licensed medical practitioner.